Keywords
Eligibility Determination ×
Dermatology ×
Show more Keywords
Table of contents
  1. 1. Clinical Trial
  2. 2. Routine Documentation
  3. 3. Registry/Cohort Study
  4. 4. Quality Assurance
  5. 5. Data Standard
  6. 6. Patient-Reported Outcome
  7. 7. Medical Specialty
Selected data models

You must log in to select data models for download or further analysis.

67 Search results.

Clinical activity of recMAGE-A3 + AS15 in patients with metastatic cutaneous melanoma NCT00942162 - Eligibility Check (Annex Report 2 Final)

- 10/29/20 - 1 form, 4 itemgroups, 29 items, 1 language
Itemgroups: Administrative, Eligibility Check, Inclusion Criteria, Exclusion Criteria
Study ID: 111476 Clinical Study ID: 111476 Study Title: An open, single-arm trial to assess the clinical activity of recMAGE-A3 + AS15 in patients with unresectable MAGE-A3-positive metastatic cutaneous melanoma Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00942162 Sponsor: GlaxoSmithKline Phase: Phase 2 Study Recruitment Status: Completed Generic Name: Antigen-Specific Cancer Immunotherapeutic Study Indication: Melanoma

Clinical activity of recMAGE-A3 + AS15 in patients with metastatic cutaneous melanoma NCT00942162 - Eligibility Check

- 8/25/20 - 1 form, 4 itemgroups, 29 items, 1 language
Itemgroups: Administrative, Eligibility Check, Inclusion Criteria, Exclusion Criteria
Study ID: 111476 Clinical Study ID: 111476 Study Title: An open, single-arm trial to assess the clinical activity of recMAGE-A3 + AS15 in patients with unresectable MAGE-A3-positive metastatic cutaneous melanoma Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00942162 Sponsor: GlaxoSmithKline Phase: Phase 2 Study Recruitment Status: Completed Generic Name: Antigen-Specific Cancer Immunotherapeutic Study Indication: Melanoma

Eligibility High Risk Cutaneous Squamous Cell Carcinoma NCT01252329

- 2/27/20 - 1 form, 2 itemgroups, 16 items, 1 language
Itemgroups: Criteria, Exclusion Criteria
Comparison of Elective Lymph Node Treatment Versus Clinical Observation in the Absence of Palpable Lymph Nodes for High Risk Skin Squamous Cell Carcinoma (SCC); ODM derived from: https://clinicaltrials.gov/show/NCT01252329

Eligibility Dysplasia NCT01140178

- 12/3/19 - 1 form, 2 itemgroups, 19 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
A Trial of Photodynamic Therapy With HPPH for Treatment of Dysplasia, Carcinoma in Situ and T1 Carcinoma of the Oral Cavity and/or Oropharynx; ODM derived from: https://clinicaltrials.gov/show/NCT01140178

Eligibility Diabetic Foot Ulcer NCT01813305

- 11/28/19 - 1 form, 2 itemgroups, 17 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
CSTC1 for Diabetic Foot Ulcers Phase II Study; ODM derived from: https://clinicaltrials.gov/show/NCT01813305

Eligibility Carcinoma, Squamous Cell NCT02281955

- 10/25/19 - 1 form, 2 itemgroups, 18 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
De-intensification of Radiation and Chemotherapy for Low-Risk HPV-related Oropharyngeal SCC: Follow-up Study; ODM derived from: https://clinicaltrials.gov/show/NCT02281955

Eligibility Carcinoma, Squamous Cell of Head and Neck NCT01417936

- 10/18/19 - 1 form, 2 itemgroups, 14 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Sym004 in Subjects With Squamous Cell Carcinoma of Head and Neck (SCCHN) Failing Anti-Epidermal Growth Factor Receptor (Anti-EGFR) Based Therapy; ODM derived from: https://clinicaltrials.gov/show/NCT01417936

Eligibility Squamous Cell Carcinoma of Skin NCT02218164

- 7/12/19 - 1 form, 2 itemgroups, 15 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Pegylated Interferon Alpha-2b and Capecitabine in Unresectable/Metastatic Cutaneous Squamous Cell; ODM derived from: https://clinicaltrials.gov/show/NCT02218164

Eligibility Stage IIIB Merkel Cell Carcinoma NCT02465957

- 7/12/19 - 1 form, 2 itemgroups, 22 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Study of Neukoplast (NK-92) Infusions in Patients With Unresectable Stage III (IIIB) or Distant Metastatic (IV) Merkel Cell Carcinoma (MCC); ODM derived from: https://clinicaltrials.gov/show/NCT02465957

Eligibility Seasonal Allergic Rhinitis NCT02061670

- 7/7/19 - 1 form, 2 itemgroups, 11 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Safety Study of Ragweed-SPIRE in Subjects With Ragweed Allergies and Asthma; ODM derived from: https://clinicaltrials.gov/show/NCT02061670

Eligibility Recurrent Hypopharyngeal Squamous Cell Carcinoma NCT02388932

- 6/27/19 - 1 form, 2 itemgroups, 14 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Stereotactic Body Radiation Therapy in Treating Patients With High Risk Locally Advanced Head and Neck Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT02388932

Eligibility Psoriatic Arthritis NCT02029495

- 6/26/19 - 1 form, 2 itemgroups, 9 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Study of Efficacy, Safety and Effect on Radiographic Progession of Brodalumab in Subjects With Psoriatic Arthritis; ODM derived from: https://clinicaltrials.gov/show/NCT02029495